Effects of COVID-19 vaccination on irAEs and prognosis in lung cancer patients receive PD-(L)1 inhibitors
The influence of COVID-19 vaccination on the efficacy and safety of immune checkpoint inhibitors (ICIs) in lung cancer treatment is not well understood. A cohort of 394 lung cancer patients treated with PD-1/PD-L1 inhibitors was analyzed. The incidence and types of irAEs were recorded, and the relat...
Saved in:
| Main Authors: | Ping Luo, Jiasi Liu, Zhan Wang, Chenwei Liao, Lei She, Ting Zou, Juan Chen, Zhaoqian Liu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2025.2539593 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Peripheral blood markers predict prognosis and irAEs of stage IV driver gene-negative lung adenocarcinoma treated with ICIs
by: Yu Li, et al.
Published: (2025-03-01) -
Antiviral therapy can effectively suppress irAEs in HBV positive hepatocellular carcinoma treated with ICIs: validation based on multi machine learning
by: Shuxian Pan, et al.
Published: (2025-01-01) -
Editorial for “a predictive model for irAEs in ESCC patients treated with PD-1 inhibitors based on blood indicators”
by: Yaser Soleimani, et al.
Published: (2025-12-01) -
The baseline circulating immunophenotype characteristics associate with PD(L)-1 targeted treatment response, irae onset, and prognosis
by: Xiaomin Fu, et al.
Published: (2025-05-01) -
A review of immune checkpoint inhibitor-associated myocarditis: Epidemiology, pathogenesis, and biomarkers
by: Le Xu, et al.
Published: (2025-12-01)